Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Summary

This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.

Timeline

Start

2009-06

Primary completion

2009-12

Completion

2010-01

Outcome

Outcome not reported

Stopped: “Potential for immune stimulation to interfere with further dose escalation.”

Drugs

Indications

No indication recorded.